Skip to main content
. 2024 Feb 3;9:22. doi: 10.1038/s41541-024-00813-3

Fig. 2. HBV mRNA vaccine induced efficient and sustained viral suppression and achieved robust seroconversion in rAAV8-HBV1.3 mice.

Fig. 2

a Study design. rAAV-HBV1.3-transduced HBV-carrier mice (n = 6/group) were immunized i.m. with 5 μg or 10 μg HBV mRNA vaccines three times at a 1-week interval. HBV-carrier mice administered with PBS were used as control. Sera samples were collected longitudinally. b Levels of serum HBsAg were measured at the indicated time points. 208 days after treatment start, levels of serum HBeAg (c), serum HBV DNA copies (d), and anti-HBs Abs (e) were measured. An unpaired, two-tailed Student’s t test was used for statistical analysis. Data are shown as Mean ± SEM. *p ≤ 0.05, **p ≤ 0.01. PEIU represents Paul-Ehrlich-Institute Unit.